✨
AI Summary
- Lotte Bjerre Knudsen, Novo Nordisk's Chief Scientific Advisor, led research in the early 1990s that first invented semaglutide, explaining the molecular mechanism behind Ozempic's weight loss effects
- Weight loss was a goal from the very start of development, contrary to popular narratives portraying it as an accidental side effect of diabetes medication
- Knudsen persisted in pursuing the molecule through years when the industry and even her own company had written off weight loss treatments as unsolvable
Guests on This Episode
LK
Lotte Bjerre Knudsen
1 podcast appearance